25 November 2014, 6:30 pm
A group of community organisations working on HIV prevention have called for the NHS to speed up its processes and make pre-exposure prophylaxis (PrEP) available to those at the highest risk of acquiring HIV. The organisations point to the continued high rate of new infections and say there is an urgent need to improve

25 November 2014, 8:30 am
Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in Boston, United States. Serological response rates continued to increase over time and kidney and bone-related side-effects remained

25 November 2014, 7:10 am
An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus genotype 3 in the phase 3 ALLY-3 trial, researchers reported earlier this month at the American Association for the Study of

24 November 2014, 8:50 am
A US study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that used $70 gift tokens as an incentive for people to attend clinic regularly, refill their HIV treatment drug prescriptions, and maintain an undetectable viral load. However, the study found

21 November 2014, 9:20 am
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most people with HIV and hepatitis C virus (HCV) co-infection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD)

1 2

    • No upcoming events
  • View All Add your news